BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31878806)

  • 1. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
    Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The place of selective progesterone receptor modulators in myoma therapy.
    Donnez J; Donnez O; Courtoy GE; Dolmans MM
    Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vilaprisan for treating uterine fibroids.
    Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
    Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
    Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
    Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
    [No Abstract]   [Full Text] [Related]  

  • 6. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
    Donnez J; Courtoy GE; Donnez O; Dolmans MM
    Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial.
    Liu JH; Soper D; Lukes A; Gee P; Kimble T; Kroll R; Mallick M; Chan A; Gillard P; Harrington A; Sniukiene V; Shulman LP
    Obstet Gynecol; 2018 Nov; 132(5):1241-1251. PubMed ID: 30303900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Ulipristal Acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding.
    Arendas K; Leyland NA
    J Obstet Gynaecol Can; 2016 Jan; 38(1):80-3. PubMed ID: 26872761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of ulipristal acetate in female patients with uterine fibroids.
    Grzechocinska B; Gadomska H; Zygula A; Wielgos M
    Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas.
    Gracia M; Alcalà M; Ferreri J; Rius M; Ros C; Saco MA; Martínez-Zamora MÁ; Carmona F
    J Minim Invasive Gynecol; 2018; 25(7):1274-1280. PubMed ID: 29626678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
    Demura TA; Revazova ZV; Kogan EA; Adamyan LV
    Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment.
    Courtoy GE; Henriet P; Marbaix E; de Codt M; Luyckx M; Donnez J; Dolmans MM
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1566-1573. PubMed ID: 29408988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
    Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
    Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of selective progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J
    Ceska Gynekol; 2016; 81(4):317-320. PubMed ID: 27882756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of symptomatic uterine fibroids with ulipristal acetate: A retrospective, multicentric and nationwide study.
    Águas F; Guerreiro F; Ponte C; Gomes C; Martinho M; Vilhena V; Silva D
    J Gynecol Obstet Hum Reprod; 2020 Oct; 49(8):101862. PubMed ID: 32652302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.